(PHIA) Koninklijke Philips - Ratings and Ratios
Exchange: AS •
Country: Netherlands •
Currency: EUR •
Type: Common Stock •
ISIN: NL0000009538
Imaging, Monitoring, Homecare, Grooming, Dental
PHIA EPS (Earnings per Share)
PHIA Revenue
Description: PHIA Koninklijke Philips October 14, 2025
Koninklijke Philips N.V. (PHIA) is a global health-technology company organized into three segments: Diagnosis & Treatment, Connected Care, and Personal Health. The firm sells diagnostic imaging equipment (MRI, X-ray, CT, ultrasound), interventional imaging systems, acute and home-care patient-management solutions, as well as consumer health products such as power toothbrushes and infant-care devices.
In FY 2023 Philips reported €22.4 billion in revenue, with the Diagnosis & Treatment segment contributing roughly 55 % of total sales and delivering a 12 % operating margin, while Connected Care grew at a 9 % CAGR over the past three years driven by expanding tele-health adoption. R&D intensity remains high at about 7 % of revenue, reflecting the company’s focus on AI-enabled imaging and software platforms. Key macro drivers include rising US healthcare expenditure (projected to exceed 18 % of GDP by 2027) and accelerating demand for digital and remote patient-monitoring solutions in aging populations.
For a deeper, data-driven assessment of Philips’ valuation and risk profile, you may find the analytics on ValueRay worth a look.
PHIA Stock Overview
| Market Cap in USD | 25,975m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception |
PHIA Stock Ratings
| Growth Rating | 33.5% |
| Fundamental | 47.6% |
| Dividend Rating | 45.1% |
| Return 12m vs S&P 500 | -15.0% |
| Analyst Rating | - |
PHIA Dividends
| Dividend Yield 12m | 3.47% |
| Yield on Cost 5y | 2.55% |
| Annual Growth 5y | 0.00% |
| Payout Consistency | 81.5% |
| Payout Ratio | 84.2% |
PHIA Growth Ratios
| Growth Correlation 3m | 44.9% |
| Growth Correlation 12m | -18.5% |
| Growth Correlation 5y | -27.8% |
| CAGR 5y | 29.04% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.86 |
| CAGR/Mean DD 3y (Pain Ratio) | 2.71 |
| Sharpe Ratio 12m | 0.62 |
| Alpha | -17.59 |
| Beta | 0.843 |
| Volatility | 36.48% |
| Current Volume | 3188.2k |
| Average Volume 20d | 1200.6k |
| Stop Loss | 23.7 (-3.4%) |
| Signal | 1.34 |
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (162.0m TTM) > 0 and > 6% of Revenue (6% = 1.07b TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA -1.92pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 10.43% (prev 7.59%; Δ 2.84pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 1.10b > Net Income 162.0m (YES >=105%, WARN >=100%) |
| Net Debt (6.60b) to EBITDA (1.62b) ratio: 4.08 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.26 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (950.6m) change vs 12m ago 1.76% (target <= -2.0% for YES) |
| Gross Margin 43.85% (prev 41.56%; Δ 2.29pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 63.94% (prev 61.52%; Δ 2.42pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.33 (EBITDA TTM 1.62b / Interest Expense TTM 323.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.30
| (A) 0.07 = (Total Current Assets 9.06b - Total Current Liabilities 7.20b) / Total Assets 26.38b |
| (B) 0.12 = Retained Earnings (Balance) 3.03b / Total Assets 26.38b |
| (C) 0.04 = EBIT TTM 1.08b / Avg Total Assets 27.93b |
| (D) 0.19 = Book Value of Equity 3.03b / Total Liabilities 15.97b |
| Total Rating: 1.30 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 47.57
| 1. Piotroski 4.0pt = -1.0 |
| 2. FCF Yield 1.51% = 0.75 |
| 3. FCF Margin 2.46% = 0.61 |
| 4. Debt/Equity 0.81 = 2.18 |
| 5. Debt/Ebitda 4.08 = -2.50 |
| 6. ROIC - WACC (= -2.30)% = -2.87 |
| 7. RoE 1.41% = 0.12 |
| 8. Rev. Trend -20.17% = -1.51 |
| 9. EPS Trend 35.79% = 1.79 |
What is the price of PHIA shares?
As of November 05, 2025, the stock is trading at EUR 24.53 with a total of 3,188,196 shares traded.
Over the past week, the price has changed by +5.01%, over one month by +2.08%, over three months by +6.42% and over the past year by +2.01%.
Over the past week, the price has changed by +5.01%, over one month by +2.08%, over three months by +6.42% and over the past year by +2.01%.
Is Koninklijke Philips a good stock to buy?
No, based on ValueRay´s Fundamental Analyses, Koninklijke Philips (AS:PHIA) is currently (November 2025)
a stock to sell. It has a ValueRay Fundamental Rating of 47.57 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PHIA is around 22.83 EUR . This means that PHIA is currently overvalued and has a potential downside of -6.93%.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PHIA is around 22.83 EUR . This means that PHIA is currently overvalued and has a potential downside of -6.93%.
Is PHIA a buy, sell or hold?
Koninklijke Philips has no consensus analysts rating.
What are the forecasts/targets for the PHIA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 26.8 | 9.3% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 25.1 | 2.2% |
PHIA Fundamental Data Overview January 01, 1970
Market Cap USD = 25.98b (22.54b EUR * 1.1525 EUR.USD)
Market Cap EUR = 22.54b (22.54b EUR * 1.0 EUR.EUR)
P/E Trailing = 148.1875
P/E Forward = 14.6413
P/S = 1.2623
P/B = 2.1862
P/EG = 0.3634
Beta = 0.843
Revenue TTM = 17.86b EUR
EBIT TTM = 1.08b EUR
EBITDA TTM = 1.62b EUR
Long Term Debt = 7.18b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.24b EUR (from shortLongTermDebt, last quarter)
Debt = 8.43b EUR (Calculated: Short Term 1.24b + Long Term 7.18b)
Net Debt = 6.60b EUR (from netDebt column, last quarter)
Enterprise Value = 29.14b EUR (22.54b + Debt 8.43b - CCE 1.82b)
Interest Coverage Ratio = 3.33 (Ebit TTM 1.08b / Interest Expense TTM 323.0m)
FCF Yield = 1.51% (FCF TTM 439.0m / Enterprise Value 29.14b)
FCF Margin = 2.46% (FCF TTM 439.0m / Revenue TTM 17.86b)
Net Margin = 0.91% (Net Income TTM 162.0m / Revenue TTM 17.86b)
Gross Margin = 43.85% ((Revenue TTM 17.86b - Cost of Revenue TTM 10.03b) / Revenue TTM)
Gross Margin QoQ = 46.36% (prev 45.13%)
Tobins Q-Ratio = 1.10 (Enterprise Value 29.14b / Total Assets 26.38b)
Interest Expense / Debt = 0.95% (Interest Expense 80.0m / Debt 8.43b)
Taxrate = 28.19% (95.0m / 337.0m)
NOPAT = 773.4m (EBIT 1.08b * (1 - 28.19%))
Current Ratio = 1.26 (Total Current Assets 9.06b / Total Current Liabilities 7.20b)
Debt / Equity = 0.81 (Debt 8.43b / totalStockholderEquity, last quarter 10.38b)
Debt / EBITDA = 4.08 (Net Debt 6.60b / EBITDA 1.62b)
Debt / FCF = 15.04 (Net Debt 6.60b / FCF TTM 439.0m)
Total Stockholder Equity = 11.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.61% (Net Income 162.0m / Total Assets 26.38b)
RoE = 1.41% (Net Income TTM 162.0m / Total Stockholder Equity 11.49b)
RoCE = 5.77% (EBIT 1.08b / Capital Employed (Equity 11.49b + L.T.Debt 7.18b))
RoIC = 4.52% (NOPAT 773.4m / Invested Capital 17.09b)
WACC = 6.82% (E(22.54b)/V(30.96b) * Re(9.12%) + D(8.43b)/V(30.96b) * Rd(0.95%) * (1-Tc(0.28)))
Discount Rate = 9.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.82%
[DCF Debug] Terminal Value 65.74% ; FCFE base≈685.4m ; Y1≈450.0m ; Y5≈205.8m
Fair Price DCF = 3.58 (DCF Value 3.41b / Shares Outstanding 950.6m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 35.79 | EPS CAGR: 308.2% | SUE: 0.42 | # QB: 0
Revenue Correlation: -20.17 | Revenue CAGR: 0.24% | SUE: 0.00 | # QB: 0
Market Cap EUR = 22.54b (22.54b EUR * 1.0 EUR.EUR)
P/E Trailing = 148.1875
P/E Forward = 14.6413
P/S = 1.2623
P/B = 2.1862
P/EG = 0.3634
Beta = 0.843
Revenue TTM = 17.86b EUR
EBIT TTM = 1.08b EUR
EBITDA TTM = 1.62b EUR
Long Term Debt = 7.18b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.24b EUR (from shortLongTermDebt, last quarter)
Debt = 8.43b EUR (Calculated: Short Term 1.24b + Long Term 7.18b)
Net Debt = 6.60b EUR (from netDebt column, last quarter)
Enterprise Value = 29.14b EUR (22.54b + Debt 8.43b - CCE 1.82b)
Interest Coverage Ratio = 3.33 (Ebit TTM 1.08b / Interest Expense TTM 323.0m)
FCF Yield = 1.51% (FCF TTM 439.0m / Enterprise Value 29.14b)
FCF Margin = 2.46% (FCF TTM 439.0m / Revenue TTM 17.86b)
Net Margin = 0.91% (Net Income TTM 162.0m / Revenue TTM 17.86b)
Gross Margin = 43.85% ((Revenue TTM 17.86b - Cost of Revenue TTM 10.03b) / Revenue TTM)
Gross Margin QoQ = 46.36% (prev 45.13%)
Tobins Q-Ratio = 1.10 (Enterprise Value 29.14b / Total Assets 26.38b)
Interest Expense / Debt = 0.95% (Interest Expense 80.0m / Debt 8.43b)
Taxrate = 28.19% (95.0m / 337.0m)
NOPAT = 773.4m (EBIT 1.08b * (1 - 28.19%))
Current Ratio = 1.26 (Total Current Assets 9.06b / Total Current Liabilities 7.20b)
Debt / Equity = 0.81 (Debt 8.43b / totalStockholderEquity, last quarter 10.38b)
Debt / EBITDA = 4.08 (Net Debt 6.60b / EBITDA 1.62b)
Debt / FCF = 15.04 (Net Debt 6.60b / FCF TTM 439.0m)
Total Stockholder Equity = 11.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.61% (Net Income 162.0m / Total Assets 26.38b)
RoE = 1.41% (Net Income TTM 162.0m / Total Stockholder Equity 11.49b)
RoCE = 5.77% (EBIT 1.08b / Capital Employed (Equity 11.49b + L.T.Debt 7.18b))
RoIC = 4.52% (NOPAT 773.4m / Invested Capital 17.09b)
WACC = 6.82% (E(22.54b)/V(30.96b) * Re(9.12%) + D(8.43b)/V(30.96b) * Rd(0.95%) * (1-Tc(0.28)))
Discount Rate = 9.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.82%
[DCF Debug] Terminal Value 65.74% ; FCFE base≈685.4m ; Y1≈450.0m ; Y5≈205.8m
Fair Price DCF = 3.58 (DCF Value 3.41b / Shares Outstanding 950.6m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 35.79 | EPS CAGR: 308.2% | SUE: 0.42 | # QB: 0
Revenue Correlation: -20.17 | Revenue CAGR: 0.24% | SUE: 0.00 | # QB: 0